CIP
PBYI icon

Chartwell Investment Partners’s Puma Biotechnology PBYI Stock Holding History

Chartwell Investment Partners’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-39,098
Closed -$3.87M – 424
2017
Q4 		$3.87M Sell
39,098
-3,742
-9% -$419K 0.13% 241
2017
Q3 		$5.13M Buy
42,840
+24,194
+130% +$2.25M 0.18% 186
2017
Q2 		$1.63M Buy
+18,646
New +$1.04M 0.06% 315
2015
Q2 		– Sell
-107,254
Closed -$25.3M – 327
2015
Q1 		$25.3M Buy
+107,254
New +$22.9M 0.49% 59

Other funds holding PBYI

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Chartwell Investment Partners's PBYI Position: Q1 2018 in Review

Chartwell Investment Partners sold out of Puma Biotechnology (PBYI) in Q1 2018, closing a stake of 39,098 shares — an estimated $3.87M sold.

Chartwell Investment Partners first reported a position in PBYI in Q1 2015 and held it in 4 quarters. The position peaked at $25.3M in Q1 2015. 178 funds tracked by Wall St. Rank hold PBYI as of Q1 2018.

  • Chartwell Investment Partners reported no remaining Puma Biotechnology position as of Q1 2018 after selling out during the quarter.
  • Chartwell Investment Partners sold 39,098 Puma Biotechnology shares in Q1 2018, an estimated $3.87M.
  • Chartwell Investment Partners first reported a position in Puma Biotechnology in Q1 2015 and held it in 4 quarters.
  • Chartwell Investment Partners's Puma Biotechnology position peaked at $25.3M in Q1 2015.
  • 178 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2018.

Based on Chartwell Investment Partners's 13F filing for Q1 2018, filed 8 May 2018.